Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  orteronel
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-12 of 12 for your search:
Start Over
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C21004, 2010-018661-35, NCT01193244
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C21005, 2010-018662-23, CTR20131423, NCT01193257
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG 1115, CDR0000727326, NCI-2012-00700, NCT01546987
Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy
Phase: Phase III
Type: Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: Other
Protocol IDs: SAKK 08/11, 2011-002965-39, NCT01707966
Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents
Phase: Phase III
Type: Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: Other
Protocol IDs: SAKK 08/13, 2013-004912-23, NCT02053311
Safety Study of TAK-700 in Subjects With Prostate Cancer.
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TAK-700_201, NCT00569153
Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C21003, NCT01084655
Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C21013, 2012-001539-30, NCT01666314
Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C21001, NCT01046916
Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C21012, 2012-000136-26, NCT01549951
NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CO12810, NCT01816048
CO11109: A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012-0355, NCT01808040
Start Over